[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Equillium\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100659712","phase-1-a-phase-i-randomized-double-blind-placebo-controlled-study-of-eq504-in-single-and-multiple-ascending-doses-in-healthy-volunteers-100659712",false,"NCT07869225","A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered EQ504 in Healthy Volunteers","Inclusion Criteria:\n\n* Males and females 18 to 65 years of age inclusive\n* Body mass index (BMI) 18 to 32 kg\u002Fm2, with a body weight greater than or equal to 55kg\n* Medically healthy without clinically significant abnormalities\n* Have suitable venous access for blood sampling\n\nExclusion Criteria:\n\n* History of chronic alcohol abuse or excessive alcohol intake\n* History of substance abuse or drug addiction within 1 year prior to first study drug administration and positive drug test results\n* Smoke more than 5 nicotine containing products or equivalent per month or who are not willing to abstain from smoking 7 days prior to admission and during the confinement period(s)\n* History of relevant drug hypersensitivity\n* Receiving or has received any investigational drug (biologic or small molecule) or is currently using an investigational device, within 3 months prior to trial Day 1\n* Positive for HIV-1 or HIV-2, hepatitis B virus (HBV), or Hepatitis C virus (HCV)\n* Donation or receipt of blood or blood products within 90 days prior to screening\n* Past or intended use of over-the-counter or prescription medication (except for contraceptives), including herbal medications and AhR modulators (approved or investigational drug) within 14 days or 5 half-lives, whichever is longer, prior to dosing or during the trial\n* Live vaccine(s) within 1 month prior to Screening or plans to receive such vaccines during the trial.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a Phase 1, first in human, three-part randomized, double-blind, placebo-controlled dose escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of EQ504 following single ascending dose (SAD) and multiple ascending dose administration (MAD), and an optional food effect (FE) cohort in healthy volunteers. The study will be conducted at a single site. Approximately 40 subjects will be enrolled in SAD, 30 in MAD, and 8 in FE.",[28],"Ulcerative Colitis","NOT_YET_RECRUITING","2026-10-06",{"date":32,"type":33},"2026-10-09","ACTUAL",{"date":35,"type":22},"2026-10",{"date":37,"type":22},"2027-05",{"name":39,"class":40},"Equillium","INDUSTRY",""]